Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Analysts at Jefferies Group dropped their FY2018 earnings per share (EPS) estimates for Vanda Pharmaceuticals in a research note issued to investors on Tuesday. Jefferies Group analyst M. Andrews now forecasts that the biopharmaceutical company will post earnings per share of ($0.98) for the year, down from their prior estimate of ($0.72). Jefferies Group currently has a “Buy” rating and a $20.00 target price on the stock. Jefferies Group also issued estimates for Vanda Pharmaceuticals’ FY2019 earnings at $0.85 EPS, FY2020 earnings at $0.60 EPS, FY2021 earnings at $1.00 EPS and FY2022 earnings at $2.07 EPS.
Several other research firms have also recently issued reports on VNDA. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a report on Wednesday, October 18th. Piper Jaffray Companies set a $26.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, October 19th. Oppenheimer set a $27.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday. BidaskClub raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Finally, ValuEngine raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $21.43.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.08. Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The business had revenue of $44.28 million for the quarter, compared to analysts’ expectations of $44.00 million. During the same period in the previous year, the company posted $0.08 earnings per share. The business’s revenue for the quarter was up 15.8% compared to the same quarter last year.
In other news, insider Mihael Hristos Polymeropoulos sold 191,760 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $15.30, for a total transaction of $2,933,928.00. Following the completion of the transaction, the insider now owns 1,031,848 shares in the company, valued at $15,787,274.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James Patrick Kelly sold 9,155 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $15.35, for a total transaction of $140,529.25. Following the transaction, the chief financial officer now owns 144,721 shares of the company’s stock, valued at approximately $2,221,467.35. The disclosure for this sale can be found here. In the last quarter, insiders have sold 209,483 shares of company stock valued at $3,205,205. 7.60% of the stock is owned by insiders.
Hedge funds have recently bought and sold shares of the stock. Teacher Retirement System of Texas acquired a new stake in Vanda Pharmaceuticals in the fourth quarter worth about $209,000. Metropolitan Life Insurance Co. NY acquired a new stake in Vanda Pharmaceuticals in the fourth quarter worth about $221,000. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Vanda Pharmaceuticals in the third quarter worth about $277,000. Voya Investment Management LLC lifted its holdings in Vanda Pharmaceuticals by 29.7% in the second quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock worth $328,000 after purchasing an additional 4,605 shares during the period. Finally, Dynamic Technology Lab Private Ltd lifted its holdings in Vanda Pharmaceuticals by 46.3% in the second quarter. Dynamic Technology Lab Private Ltd now owns 20,510 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 6,487 shares during the period. 88.19% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This report was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.chaffeybreeze.com/2018/02/15/fy2018-eps-estimates-for-vanda-pharmaceuticals-inc-lowered-by-analyst-vnda.html.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.